Detalhe da pesquisa
1.
CK-2127107 amplifies skeletal muscle response to nerve activation in humans.
Muscle Nerve
; 57(5): 729-734, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150952
2.
Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.
Muscle Nerve
; 50(6): 925-31, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24634285
3.
Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease.
Vasc Med
; 19(4): 297-306, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24872402
4.
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 25(1-2): 162-169, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641579
5.
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(3-4): 304-310, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503310
6.
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
J Med Econ
; 26(1): 488-493, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930042
7.
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(5-6): 523-534, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37254449
8.
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lancet
; 378(9792): 667-75, 2011 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21856480
9.
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Lancet
; 378(9792): 676-83, 2011 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21856481
10.
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Anticancer Drugs
; 23(3): 335-41, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22123335
11.
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler
; 13(5): 430-8, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22591195
12.
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 23(3-4): 263-270, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34218726
13.
Noninvasive ventilation use by patients enrolled in VITALITY-ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 22(7-8): 486-494, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792451
14.
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Neurotherapeutics
; 18(2): 1127-1136, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624184
15.
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 22(3-4): 287-299, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969758
16.
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener
; 0(0): 1-11, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31081694
17.
Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.
Amyotroph Lateral Scler Frontotemporal Degener
; 19(7-8): 506-512, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30379086
18.
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
JAMA Neurol
; 75(1): 58-64, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29181534
19.
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Amyotroph Lateral Scler Frontotemporal Degener
; 19(3-4): 259-266, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29402141
20.
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
JAMA
; 297(16): 1775-83, 2007 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17456819